TB R&D Update: Podcast Interview with Dr. Iwao Ojima
Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. In this interview, Dr. Ojima discusses the work his lab has...
View ArticleKick TB Campaign Expands to Brazil
The Kick TB Campaign is a unique project that uses the World’s most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis. First inaugurated in South Africa...
View ArticlePanel of TB experts releases report calling for the prioritization of...
The Center for Strategic and International Studies (CSIS) released six policy reports detailing the domestic and global health burden of tuberculosis and recommendations for the United States...
View ArticleTB R&D Update: Tuberculosis enzyme, isocitrate lyase, grants bacterium...
A new study published by Dr. Kyu Rhee’s laboratory at the Weill Cornell Medical College details a potential mechanism driving Mycobacterium tuberculosis’ intrinsic resistance to antibiotics.
View ArticleTB R&D Update: Scientists discover a new resistance mechanism to second line...
Scientists at Janssen Pharmaceutica have characterized a novel resistance mechanism to Bedaquiline (BDQ), a second line antibiotic for the treatment of MDR-TB.
View ArticleResults of Phase III ReMoxTB Clinical Trial Published
Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a...
View Article2014 WGND Annual Meeting, Barcelona, Oct. 29, 15h-19h
We invite you to join us for the Stop TB Partnership Working Group on New Drugs' Annual Meeting 2014 at AC Hotel Barcelona Forum, Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00.
View Article2014 Report on Tuberculosis Research Funding Trends, 2005–2013
Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2...
View ArticleTB R&D Update: New treatment strategy using Bedaquiline in combination with...
Researchers at Johns Hopkins University School of Medicine have shown that heart medication, Verapamil administered in combination with Bedaquline lowers the toxicity of the TB drug without altering...
View ArticleTB Alliance Drug,TBA-354, enters Phase I Clinical Trials
TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009
View Article
